In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takara Bio Inc.

Division of Takara Holdings Inc.
www.takara-bio.com

Latest From Takara Bio Inc.

Innovation The Centerpiece In Mixed Japan 2019 Outlook

2019 has already brought one industry-shaking event in Japan with the formal completion of the Takeda-Shire deal. But how will this play out and what else can we expect in this key market over the next year?

Japan Commercial

Deal Watch: Emergent Strikes Again, Acquiring Adapt And Its Opioid Overdose Drug For $635m

Following its purchase of PaxVax earlier this month, Emergent is taking on Narcan nasal spray for opioid overdose as part of its acquisition of Adapt. Also-busy Evotec teams up with Centogene in rare genetic disease and Novo in diabetes/obesity.

Deals Business Strategies

Pipeline Watch: Phase III Zytiga, Cadazolid And Upadacitinib Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Device/Diagnostics Quarterly Deal Statistics, Q4 2016

Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.

Deals Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Services
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Takara Biomedical
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Takara Holdings Inc.
  • Senior Management
  • Koichi Nakao, Pres. & CEO
  • Contact Info
  • Takara Bio Inc.
    Phone: (81) 77 543 7200
    Nojihigashi 7-4-38
    Kusatsu
    Shiga, 525-0058
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register